Parathyroid Hormone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Parathyroid Hormone: From Undocumented Original Indication to Migraine Disorder
One-Sentence Summary
Parathyroid hormone (DrugBank DB05829) is an endogenous calcium/phosphate-regulating hormone whose original approved indication is not documented in the current evidence pack. The TxGNN model predicts it may be effective for Migraine Disorder, but this direction is currently supported only by 1 clinical trial (unrelated to the drug itself) and 6 publications, most of which concern PTH-related peptide receptors, vitamin D, or magnesium rather than PTH treatment itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the evidence pack (see Data Gaps DG001/DG002) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 |
| Finland Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for parathyroid hormone is not available in this evidence pack (Data Gap DG002). Based on known pharmacology, PTH is the primary endogenous regulator of serum calcium and phosphate homeostasis, acting via PTH1R/PTH2R receptors on bone and kidney.
The mechanistic case for migraine linkage comes from a single 2025 genetic-association study showing that PTHrP receptors (PTH1R/PTH2R) — not PTH itself — may act as genetic drivers of migraine susceptibility. This is an important distinction: PTHrP (parathyroid hormone-related peptide) is a related but structurally and functionally distinct molecule from PTH, and receptor-level genetic association does not establish that administering PTH would have any therapeutic effect on migraine.
A second, much older (1986) paper describes central nervous system effects of calcitonin and "parathormone" in animal/mechanistic studies, suggesting a theoretical basis for CNS activity, but this predates modern migraine pathophysiology research and offers no dosing, efficacy, or safety data. No clinical trial has directly tested PTH as a migraine treatment. Overall, the biological rationale is plausible at the receptor-family level but has not been demonstrated for PTH specifically, and the evidence base conflates PTH with PTHrP in places.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07028684 | N/A | Completed | 22 | Studied foot reflexology massage (a non-pharmacological intervention) for pain, sleep, and quality of life in women with migraine. Not a PTH drug trial; relevance graded "C" — matched only by disease name, not pharmacology. |
No clinical trial has tested parathyroid hormone as a treatment for migraine.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40297711 | 2025 | Genetic association review | Brain Communications | Identifies PTHrP receptors (PTH1R/PTH2R) as candidate genetic drivers of migraine susceptibility — receptor-family association, not PTH treatment evidence. |
| 24714817 | 2014 | RCT (Vitamin D, not PTH) | Braz J Med Biol Res | Vitamin D add-on to amitriptyline reduced pediatric migraine attack frequency; unrelated to PTH pharmacologically. |
| 31261815 | 2019 | Cohort (Vitamin D, not PTH) | Medicina (Kaunas) | Investigated vitamin D deficiency and response to therapy in childhood migraine; no PTH intervention studied. |
| 29429076 | 2018 | Review | Neuromolecular Medicine | Reviews cardiovascular autonomic dysfunction, osteoporosis, and neurodegeneration in multiple sclerosis; only tangentially touches bone/PTH physiology, not migraine treatment. |
| 11425281 | 2001 | Review (Magnesium, not PTH) | Medical Hypotheses | Broad review of magnesium deficiency pathology, mentioning migraine among many conditions; not PTH-related. |
| 3739765 | 1986 | Mechanistic/animal study | Acta Neurologica | Early study of central effects of calcitonin and parathormone; theoretical CNS mechanism only, no clinical efficacy data. |
None of the identified literature directly evaluates PTH as a migraine therapy; the most relevant paper (40297711) implicates a related receptor family (PTHrP receptors) rather than PTH itself.
Safety Considerations
Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data for parathyroid hormone are not currently available in this evidence pack (Data Gap DG001, classified as Blocking — this gap prevents the candidate from entering the S1 safety pre-assessment stage).
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link relies on a genetic association involving PTHrP receptors rather than PTH itself, no clinical trial has tested PTH for migraine treatment, and the evidence level (L4) reflects preclinical/mechanistic support only. Additionally, a Blocking data gap in TFDA/package-insert safety information (DG001) prevents any safety pre-assessment, and the drug is not currently marketed in Finland.
To proceed, the following is needed:
- Resolve Data Gap DG001: obtain TFDA/Fimea package insert warnings and contraindications to enable S1 safety pre-assessment
- Resolve Data Gap DG002: obtain confirmed mechanism of action data from DrugBank to clarify PTH vs. PTHrP receptor pharmacology
- Confirm the original approved indication(s) for parathyroid hormone, currently undocumented in this evidence pack
- Seek dedicated pharmacological or clinical studies testing PTH (not PTHrP or calcitonin) specifically in migraine populations before advancing beyond Hold
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.